Engagement of TLR2 reverses the suppressor function of conjunctiva CD4+CD25+ regulatory T cells and promotes herpes simplex virus epitope-specific CD4+CD25- effector T cell responses

Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3321-33. doi: 10.1167/iovs.10-6522.

Abstract

PURPOSE. The authors recently reported that Foxp3(+)CD4(+) CD25(+(Bright)) "natural" regulatory T cells (nT(reg) cells) are abundant in rabbit conjunctiva and suppress herpes simplex virus (HSV)-1-specific CD4(+) and CD8(+) effector T cells (T(eff) cells). However, little is known about the overall regulatory mechanisms of these nT(reg) cells. The authors investigate the regulation of conjunctiva-resident nT(reg) cells through Toll-like receptors (TLRs) and their effect on ocular mucosal T(eff) cell immunity. METHODS. CD4(+)CD25(+) nT(reg) cells were purified from naive rabbit conjunctivas, and their TLR expression profile was determined. The effects of TLR engagement on nT(reg) cell-mediated suppression of CD4(+) T(eff) cells were determined in vitro and in vivo. RESULTS. The authors found that conjunctiva-resident nT(reg) cells express high levels of TLR2 and TLR9; exposure to the TLR2 ligand lipoteichoic acid (LTA) led to the increased activation and proliferation of nT(reg) cells, and the addition of autologous APCs further increased nT(reg) cell expansion; in contrast, the TLR9 ligand CpG(2007) inhibited the proliferation of nT(reg) cells, and the addition of autologous APCs had no effect on such inhibition; nT(reg) cells treated with LTA, but not with CpG(2007), expressed IFN-γ and IL-10 mRNA, but not TGF-β; consistent with in vitro data, rabbits immunized by topical ocular drops of HSV-gD peptides + TLR2 ligand (LTA) displayed enhanced CD4(+)CD25(-) T(eff) cell immune responses when compared with HSV-gD peptides + TLR9 ligand (CpG(2007)). CONCLUSIONS. Although conjunctiva-resident CD4(+)CD25(+) nT(reg) cells express high level of TLR2 and TLR9, their suppressive function is more significantly reversed after the administration of TLR2 ligand (LTA; P < 0.005) than of TLR9 ligand (CpG(200); P > 0.005). These findings will likely help optimize the topical ocular administration of immunotherapies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • CD4 Antigens / immunology
  • Cells, Cultured
  • Conjunctiva / drug effects
  • Conjunctiva / immunology*
  • Cytokines / genetics
  • Epitopes, T-Lymphocyte / immunology*
  • Female
  • Herpesvirus 1, Human / immunology*
  • Immunity, Cellular / physiology
  • Interleukin-2 Receptor alpha Subunit / immunology
  • Ligands
  • Lipopolysaccharides / pharmacology
  • Lymphocyte Activation
  • RNA, Messenger / metabolism
  • Rabbits
  • Reverse Transcriptase Polymerase Chain Reaction
  • T-Lymphocytes, Regulatory / immunology*
  • Teichoic Acids / pharmacology
  • Toll-Like Receptor 2 / metabolism*
  • Toll-Like Receptor 9 / metabolism

Substances

  • CD4 Antigens
  • Cytokines
  • Epitopes, T-Lymphocyte
  • Interleukin-2 Receptor alpha Subunit
  • Ligands
  • Lipopolysaccharides
  • RNA, Messenger
  • Teichoic Acids
  • Toll-Like Receptor 2
  • Toll-Like Receptor 9
  • lipoteichoic acid